Sana Biotechnology to Present at June 2026 Investor Conferences
Rhea-AI Summary
Sana Biotechnology (NASDAQ:SANA) will present at two investor conferences in June 2026, providing a business overview and corporate update.
Management will speak at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, with live webcasts and 30-day replays on the investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – SANA
In the May 28 session, SANA gained 2.29%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | ATM equity raise | Neutral | -2.2% | ATM share sales raised capital but highlighted ongoing dilution and funding needs. |
| May 11 | Earnings and pipeline | Negative | -8.4% | Q1 loss and going-concern language despite collaboration and pipeline progress. |
| May 05 | Investor conference | Positive | +4.3% | Upcoming BofA conference presentation and business overview webcast. |
| Apr 27 | Preclinical data | Positive | +2.8% | Oral ASGCT presentation on preclinical in vivo CAR T candidate SG293 data. |
| Apr 13 | Strategic collaboration | Positive | +8.4% | Mayo Clinic collaboration to advance SC451 for type 1 diabetes care. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, particularly financings and strategic updates, has more often led to negative price reactions, while scientific and partnership news skew positive.
Over the last few months, Sana has balanced financing needs with strategic and scientific progress. In April 2026, it announced a collaboration with Mayo Clinic on SC451 and preclinical SG293 data at ASGCT, both followed by positive price moves. A BofA conference presentation on May 12, 2026 also coincided with gains. In contrast, the Q1 2026-05-11 results and subsequent ATM share sale in mid-May saw negative reactions. Today’s investor conference webcasts continue a pattern of frequent investor-facing updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update.
- Sana will present at the Jefferies Global Healthcare Conference at 9:20 a.m. ET on Wednesday, June 3, 2026.
- Sana will present at the Goldman Sachs 47th Annual Global Healthcare Conference at 4:00 p.m. ET on Tuesday, June 9, 2026.
The webcasts will be accessible on the Investor Relations page of Sana’s website at https://sana.com/. A replay of each presentation will be available at the same location for 30 days following the conference.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision; the Company’s participation at the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference; and the subject matter of the Company’s presentations at these conferences. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated May 11, 2026. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
